Todas las investigaciones
AutorizadoExploratorio terapéutico (Fase II)Intervencionista

Psilocybin in treatment-resistant depression

This research is exploring a new way to help people who have depression that hasn't improved with other common treatments. The study is investigating a substance called psilocybin. The main goal is to find out if taking psilocybin over four weeks can reduce the severity of depression symptoms, measured one week after the treatment period ends. This is a Phase II study, meaning it's still in the early stages of testing to see if the treatment works and is safe. It's an important step to understand if psilocybin could offer a new option for those struggling with long-term depression.

De un vistazo

Estado
Autorizado
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
LKH Graz II
Objetivo de inscripción
30
Inicio
30 Ene 2025

¿De qué trata este estudio?

This study is about a type of depression called 'treatment-resistant depression'. This means that individuals have tried different treatments for their depression, like talking therapies or antidepressant medications, but their symptoms haven't really improved. It can be very frustrating and difficult to live with, so doctors and researchers are always looking for new ways to help.

The study is specifically looking at a substance called psilocybin. You might have heard of it because it's found in certain types of mushrooms. Researchers are carefully studying it in a medical setting to understand its effects on the brain and mood. They want to see if it could be a useful treatment for people whose depression has been difficult to manage with regular care.

The main aim is to see if, after a four-week period of taking psilocybin, participants feel less depressed one week later. This will be measured using a standard questionnaire that helps doctors understand how severe someone's depression is. This is an early-stage study, so it's about exploring whether psilocybin has a positive effect and is generally safe, rather than a final stamp of approval for treatment.

Puntos clave

  • New study for depression that hasn't responded to other treatments.
  • Investigating a substance called psilocybin.
  • Aims to see if depression symptoms improve after four weeks of treatment.
  • Open to adults aged 18 and over, both men and women.
  • It's a Phase II study, meaning it's an early exploration of the treatment.

¿Quién puede ser elegible?

This study is looking for adults who are 18 years old or older. There is no upper age limit, meaning older adults can also take part.

Participants can be male or female. The most important thing is that they have 'treatment-resistant depression', which means their depression hasn't gotten better with standard treatments they've tried in the past.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have depression that hasn't improved with other treatments?
  3. Are you able to commit to a four-week treatment period and follow-up?
  4. Have you spoken to your doctor about your depression?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, you would receive the psilocybin treatment over a period of four weeks. During and after this treatment period, you would have appointments where doctors and nurses would check your health and how you're feeling. They will use questionnaires, like the Beck Depression Inventory II, to measure any changes in your depression symptoms. The study will look at your symptoms one week after the four-week treatment ends. The total length of your involvement, including follow-up, will be explained fully by the study team.

Riesgos y beneficios potenciales

Potential benefits of taking part could include an improvement in your depression symptoms, especially if other treatments haven't worked for you. However, as with any medical study, there are always potential risks; these will be fully explained to you before you decide to take part. These risks could include side effects from the medication or the experience of participating. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Ubicaciones (1)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Austria

Preguntas comunes

What is psilocybin?

Psilocybin is a natural substance found in certain mushrooms that is being studied for its potential medical uses, including for depression.

What does 'treatment-resistant depression' mean?

It means depression that hasn't improved even after trying different common treatments like talking therapies or antidepressant medications.

Will I know if I'm getting the psilocybin or a dummy treatment?

In many studies like this, participants don't know what they're receiving. The study team will explain how this works.

¿Cuánto tiempo durará el estudio para mí?

The main treatment period is four weeks, and outcomes are checked one week afterwards. The full duration of your participation will be explained by the research team.

¿Dónde se está llevando a cabo este estudio?

The information above doesn't say. The study team will be able to tell you the locations.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.